Comparison between somatostatin analog injections

Creative Commons License

Gezer E., Demirhan Y., Selek A., Cantürk Z., Cetinarslan B., Sözen M., ...More

REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, vol.68, no.4, pp.514-518, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 68 Issue: 4
  • Publication Date: 2022
  • Doi Number: 10.1590/1806-9282.20211224
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, Directory of Open Access Journals
  • Page Numbers: pp.514-518
  • Keywords: Octreotide, Lanreotide, Injection site reaction, Drug-related side effects and adverse reactions, LANREOTIDE AUTOGEL, ACROMEGALIC PATIENTS, OCTREOTIDE-LAR, THERAPY, PATIENT, TOLERABILITY, FORMULATION, MANAGEMENT, CROSSOVER, EFFICACY
  • Kocaeli University Affiliated: Yes


OBJECTIVE: Long-acting depot formulations of somatostatin analogs, i.e., octreotide and lanreotide, are the first-line medical therapies for patients with acromegaly to whom surgery/radiotherapy cannot be performed or who have inadequate response. In this study,we aimed to evaluate the short-term local and systemic adverse reactions developed after the somatostatin analogs injections in the patients with acromegaly, in order to compare the side effects of somatostatin analogs injections.